Novel |
ETV6 |
ETS variant transcription factor 6 |
- Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 fusion proteins
|
|
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
|
Novel |
SLC11A1 |
solute carrier family 11 member 1 |
- ROS and RNS production in phagocytes
- Metal ion SLC transporters
- Neutrophil degranulation
- Ion influx/efflux at host-pathogen interface
|
|
|
Novel |
ALPP |
alkaline phosphatase, placental |
|
- Calcium
- METHYL-PHOSPHONIC ACID MONO-(4-NITRO-PHENYL) ESTER
|
|
Novel |
ATP5MC3 |
ATP synthase membrane subunit c locus 3 |
- Formation of ATP by chemiosmotic coupling
- Cristae formation
|
|
|
Novel |
CAPN2 |
calpain 2 |
- Degradation of the extracellular matrix
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
|
|
|
Novel |
CDK5R2 |
cyclin dependent kinase 5 regulatory subunit 2 |
- NGF-stimulated transcription
|
|
|
Novel |
CXCR1 |
C-X-C motif chemokine receptor 1 |
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
- Neutrophil degranulation
|
|
|
Novel |
DPYSL2 |
dihydropyrimidinase like 2 |
- CRMPs in Sema3A signaling
- Recycling pathway of L1
|
|
|
Novel |
HPCA |
hippocalcin |
|
|
|
Novel |
IL1RL1 |
interleukin 1 receptor like 1 |
- PIP3 activates AKT signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Interleukin-33 signaling
|
|
|
Novel |
NUPR1 |
nuclear protein 1, transcriptional regulator |
|
|
|
Novel |
SKP1 |
S-phase kinase associated protein 1 |
- Activation of NF-kappaB in B cells
- Prolactin receptor signaling
- SCF-beta-TrCP mediated degradation of Emi1
- Vpu mediated degradation of CD4
- SCF(Skp2)-mediated degradation of p27/p21
- Degradation of beta-catenin by the destruction complex
- Downstream TCR signaling
- NOTCH1 Intracellular Domain Regulates Transcription
- Regulation of PLK1 Activity at G2/M Transition
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling
- FCERI mediated NF-kB activation
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Circadian Clock
- Dectin-1 mediated noncanonical NF-kB signaling
- CLEC7A (Dectin-1) signaling
- Degradation of GLI1 by the proteasome
- Degradation of GLI2 by the proteasome
- GLI3 is processed to GLI3R by the proteasome
- NIK-->noncanonical NF-kB signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Orc1 removal from chromatin
- Cyclin D associated events in G1
- FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
- Regulation of RUNX2 expression and activity
- Regulation of RUNX2 expression and activity
- Neddylation
- Interleukin-1 signaling
- Iron uptake and transport
- Negative regulation of NOTCH4 signaling
- Antigen processing: Ubiquitination & Proteasome degradation
|
- 1-naphthaleneacetic acid
- (2S)-2-(1H-indol-3-yl)hexanoic acid
- (2S)-2-(1H-indol-3-yl)pentanoic acid
- (2S)-8-[(tert-butoxycarbonyl)amino]-2-(1H-indol-3-yl)octanoic acid
- Indoleacetic acid
|
|
Novel |
STK16 |
serine/threonine kinase 16 |
|
|
|
Novel |
WNT6 |
Wnt family member 6 |
- WNT ligand biogenesis and trafficking
- WNT ligand biogenesis and trafficking
- Class B/2 (Secretin family receptors)
|
|
|
|
MYC |
MYC proto-oncogene, bHLH transcription factor |
- Transcription of E2F targets under negative control by DREAM complex
- NOTCH1 Intracellular Domain Regulates Transcription
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- MAPK6/MAPK4 signaling
- Ub-specific processing proteases
- Interleukin-4 and Interleukin-13 signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- TFAP2 (AP-2) family regulates transcription of cell cycle factors
- RUNX3 regulates WNT signaling
- Estrogen-dependent gene expression
- Transcriptional regulation of granulopoiesis
|
- Acetylsalicylic acid
- Nadroparin
|
- Choriocarcinoma
- Penile cancer
- Burkitt lymphoma
- Oral cancer
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
- Multiple myeloma
- Small cell lung cancer
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
- Osteosarcoma
- Kaposi's sarcoma
- Laryngeal cancer
- Breast cancer
- Ovarian cancer
|
|
EGFR |
epidermal growth factor receptor |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- EGFR Transactivation by Gastrin
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signal transduction by L1
- Constitutive Signaling by EGFRvIII
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- PTK6 promotes HIF1A stabilization
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Extra-nuclear estrogen signaling
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- HCMV Early Events
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
|
- Cetuximab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Alvocidib
- IGN311
- Matuzumab
- Vandetanib
- Rindopepimut
- Canertinib
- Pelitinib
- Varlitinib
- AV-412
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- PD-168393
- Afatinib
- Osimertinib
- Necitumumab
- Foreskin keratinocyte (neonatal)
- Depatuxizumab mafodotin
- Icotinib
- Neratinib
- Dacomitinib
- Fostamatinib
- Zalutumumab
- Brigatinib
- Olmutinib
- Zanubrutinib
- Abivertinib
|
- Choriocarcinoma
- Gastric cancer
- Bladder cancer
- Oral cancer
- Glioma
- Laryngeal cancer
- Cervical cancer
- Esophageal cancer
|
|
APC |
APC regulator of WNT signaling pathway |
- Apoptotic cleavage of cellular proteins
- Degradation of beta-catenin by the destruction complex
- Beta-catenin phosphorylation cascade
- Deactivation of the beta-catenin transactivating complex
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Signaling by GSK3beta mutants
- S33 mutants of beta-catenin aren't phosphorylated
- S37 mutants of beta-catenin aren't phosphorylated
- S45 mutants of beta-catenin aren't phosphorylated
- T41 mutants of beta-catenin aren't phosphorylated
- APC truncation mutants are not K63 polyubiquitinated
- APC truncation mutants have impaired AXIN binding
- AXIN missense mutants destabilize the destruction complex
- Truncations of AMER1 destabilize the destruction complex
- Ovarian tumor domain proteases
|
|
- Familial adenomatous polyposis
- Esophageal cancer
- Gastric cancer
- Cancer of the anal canal
- Gallbladder cancer
|
|
MAPT |
microtubule associated protein tau |
- Caspase-mediated cleavage of cytoskeletal proteins
|
- Lansoprazole
- Astemizole
- Paclitaxel
- Docetaxel
- Flortaucipir F-18
|
- Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
- Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
- Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
|
|
BRCA1 |
BRCA1 DNA repair associated |
- Meiotic synapsis
- SUMOylation of DNA damage response and repair proteins
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- TP53 Regulates Transcription of DNA Repair Genes
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Transcriptional Regulation by E2F6
- Meiotic recombination
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
|
|
- Breast cancer
- Ovarian cancer
|
|
TBCE |
tubulin folding cofactor E |
- Post-chaperonin tubulin folding pathway
|
|
- Hypoparathyroidism-retardation-dysmorphism syndrome; Sanjad-Sakati syndrome
- Kenny-Caffey syndrome
|